Merck registers Phase 3 trial testing R-DXd maintenance in advanced ovarian cancer

This week brought one new trial registration for Merck.

• A Phase 3, randomized, open-label study will test raludotatug deruxtecan (MK-5909, R-DXd) maintenance treatment, with or without bevacizumab, against standard of care in newly-diagnosed advanced non-HRD-positive ovarian cancer following first-line platinum-based chemotherapy.¹ The trial is recruiting, with an estimated enrollment of 802 participants¹, and is sponsored by Merck Sharp & Dohme with Daiichi Sankyo as collaborator. The study aims to compare progression-free survival and overall survival between the experimental arms and standard care, where the comparator arm receives bevacizumab or is followed by observation alone.¹